Skip to content
Company Analysis

Immutep Limited IMMP

A comprehensive view of key metrics, scores, and financial health for Immutep Limited

Overview of Immutep Limited

IMMP NGM
Healthcare Biotechnology Framework: Biotech / Pre-Revenue Micro Cap
Immutep Limited (IMMP), is a Micro Cap company, in the Biotechnology industry, last closed at $3.32, about 0.0% overvalued vs fair value, +75.7% 1Y return, ranked 810/1145 in sector.
Metrics Rev Growth 188.6% ROE -77.3%
USD 3.32
5.40%
(Delayed)
• Vol 90d: 1667.0%
52-Week Range
Market Cap
$24.90M
Enterprise Value
$-19.90M
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Fair
Health
Fair
Efficiency
Fair
Valuation
Weak
Growth
Fair
Profitability
Fair
Health
Fair
Efficiency
Fair
Valuation
Weak
Completeness: 76%
Confidence: 86%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.immutep.com
HQ Sydney, NSW
Fiscal year Jun 30

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$-9
$-9
$-9
Current: $3.32

Engine Room Money Flow™

Micro Cap

Biotech / Pre-Revenue - Where revenue goes and how value is created

Flow Steps
Cash on Hand
AUD 63.7M
-5.5%%
Total Revenue
AUD 14.6M
188.6%%
Net Income
-AUD 79.3M
-29.1%%
Operating Expense
AUD 96.1M
37.2%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Biotech / Pre-Revenue

Quality & Reliability Indicators

Cash Runway
12.3 months
Fair

Limited runway, likely needs financing within a year

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
0
Active Leaks
0/0
Improving
0
High Impact
0
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Immutep Limited's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
37
/100
Developing
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Operating Leverage in Effect Operating leverage is evident (score 0.89), with margins expanding over time.

Key risks

  • Commodity Pressure / Weak Differentiation Gross margin at 4.6th percentile with high volatility suggests weak pricing power or commoditized products.
  • ROIC Below WACC or Peers ROIC at 23.8th percentile suggests inefficient capital deployment.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
17
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Pre-Revenue Biotech vs Industry Peers 67% Coverage
Trade-Off Triangle Visualization A ternary plot showing IMMP's balance between Growth (34.4%), Profitability (19.8%), and Safety (45.8%). Growth 34% Safety 46% Profitability 20%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

57th percentile vs peers
58
Key Signals
TSR 3.9% 57p
Strengths
  • Cash to Debt Ratio in top 20% of peers (60.78, 89th percentile)
  • Quick Ratio in top 20% of peers (18.07, 93th percentile)
  • Strong liquidity position vs peers
Risks

No significant risks identified for this axis.

Profitability

- vs peers
-
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

77th percentile vs peers
77
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Immutep Limited.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$-8.92
- - -
- upside
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000